8-K: KALA BIO: Annual Meeting, Lazar Investment & Leadership Shift

KALA BIO announced a rescheduled annual meeting, detailed a $1.8 million preferred stock sale to David Lazar, his appointment as CEO and Board Chair, and subsequent transfer of future investment rights.

Summary

• The Annual Meeting of stockholders is scheduled for January 30, 2026, which is a delay of more than 30 days from the anniversary date of the last annual meeting.
• Deadlines for stockholder proposals under Rule 14a-8 and director nominations or other proposals under the Company's By-Laws are set for December 27, 2025.
• KALA BIO entered into a Convertible Loan Agreement with David Lazar on November 9, 2025, for an aggregate amount of $375,000.
• On November 23, 2025, the Company entered into a Securities Purchase Agreement with David Lazar for aggregate gross proceeds of up to $6.0 million from the sale of Series AA and Series AAA Convertible Non-Redeemable Preferred Stock.
• A first closing occurred on November 24, 2025, where 900,000 Series AA Preferred Shares were sold to David Lazar at $2.00 per share, generating $1.8 million in gross proceeds.
• David Lazar was appointed Chief Executive Officer (and principal executive officer) and principal financial officer, effective November 24, 2025, and November 25, 2025, respectively.
• Mr. Lazar was also elected a Class II director on November 21, 2025, and commenced serving as the Chair of the Board upon his election.
• David Lazar transferred his rights and obligations to purchase the Series AAA Preferred Shares and all other rights under the Securities Purchase Agreement to AK Holdings Group Inc., an unaffiliated investor, while retaining his Series AA Preferred Shares and the Convertible Loan Agreement.
• On December 11, 2025, a principal of AK Holdings Group Inc. was engaged as a consultant to advise the Company on identifying and consummating a strategic alternative transaction.

Sentiment

Score: 5

Explanation: The filing presents a mixed outlook. While capital was raised and new leadership appointed, the delay in the annual meeting and the transfer of future investment rights by the new CEO/Chair could be viewed with caution. The engagement of a consultant for strategic alternatives is positive, but the underlying need for such a transaction might indicate challenges.

Positives

• Secured a $375,000 convertible loan from David Lazar, providing immediate capital.
• Completed a $1.8 million private placement of Series AA Preferred Shares, further strengthening the capital position.
• Appointed David Lazar as CEO and Board Chair, bringing new leadership and strategic direction.
• Engaged a consultant from AK Holdings Group Inc. to explore and execute a strategic alternative transaction, indicating a proactive approach to future growth and value creation.

Negatives

• The Annual Meeting date is delayed by more than 30 days from the anniversary, which can sometimes signal operational or governance issues.
• David Lazar's transfer of rights to the Series AAA Preferred Shares to an unaffiliated investor might indicate a change in his long-term commitment or strategy regarding the full $6.0 million investment, potentially raising questions about future funding certainty.

Risks

• Uncertainties exist regarding the satisfaction of conditions for the Series AAA Preferred Share Closing, including the failure to obtain necessary Stockholder Approvals.
• There are uncertainties as to the timing of the consummation of the Series AAA Preferred Share Closing.
• The Company faces risks related to its ability to maintain its listing on The Nasdaq Capital Market.
• There is a risk that the Company may not be able to identify and consummate a strategic alternative transaction on the anticipated timeline or at all.

Future Outlook

The company anticipates the Series AAA Preferred Share Closing, which is subject to various conditions, including stockholder approvals. It also aims to identify and consummate a strategic alternative transaction. However, there are uncertainties regarding the timing and success of these initiatives and the Company's ability to maintain its listing on The Nasdaq Capital Market.

Management Comments

• The Board of Directors of the Company has established January 30, 2026 as the date of the Company's next annual meeting of stockholders.
• We have been advised by Mr. Lazar that he has elected to act on his Purchase Agreement Transfer Rights and has contracted to sell to an unaffiliated investor, AK Holdings Group Inc., a Panamanian company, (the Lazar Transferee) all of his interest and rights in his rights and obligation to purchase the Series AAA Preferred Shares, as well as all of his rights, titles and interest in Securities Purchase Agreement (the Lazar Sold Assets), while retaining his holdings of the Series AA Preferred Shares and the Convertible Loan Agreement.

Industry Context

NA

Management Changes

Corporate Governance

Related Party Transactions

• Convertible Loan Agreement for $375,000 with David Lazar, who subsequently became CEO and Board Chair.
• Securities Purchase Agreement for up to $6.0 million with David Lazar, involving the sale of preferred stock.
• Appointment of David Lazar as CEO, principal financial officer, Class II director, and Board Chair.

Stakeholder Impact

• Shareholders face new deadlines for proposals and nominations due to the rescheduled annual meeting. There is potential for dilution from preferred stock issuance and significant leadership changes with David Lazar taking on multiple key roles. Uncertainty exists regarding the full $6.0 million capital raise due to Lazar's transfer of rights, but there is also potential for value creation from a strategic alternative transaction.
• Management and employees will operate under significant leadership changes with David Lazar assuming the roles of CEO, principal financial officer, and Board Chair.
• Creditors are impacted by the company's capital structure changes, including the new convertible loan and preferred stock issuance.

Next Steps

• Publish additional details regarding the exact time, location, and matters to be voted on at the Annual Meeting in the Company's proxy statement.
• Hold the Annual Meeting of stockholders on January 30, 2026.
• Work towards the Series AAA Preferred Share Closing, subject to conditions and stockholder approvals.
• Identify and consummate a strategic alternative transaction with the help of the newly engaged consultant.

Key Dates

Recommendation

The company has secured some capital and appointed a new CEO and Board Chair, David Lazar, who also provided initial funding. This provides some stability and direction. However, the subsequent transfer of Lazar's rights to the larger Series AAA Preferred Share investment to another entity, coupled with the stated need for a 'strategic alternative transaction,' suggests underlying challenges or a shift in strategy. The delay in the annual meeting also raises minor governance considerations. Investors should hold to observe the outcome of the strategic review and the completion of the remaining capital raise, as well as the performance under the new leadership. The situation is too fluid for a strong buy or sell recommendation without further clarity on the strategic direction and financial health.

Keywords

KALA BIO, KALA, SEC filing, 8-K, annual meeting, stockholder proposals, director nominations, convertible loan, private placement, preferred stock, Series AA Preferred Shares, Series AAA Preferred Shares, David Lazar, AK Holdings Group Inc., CEO appointment, board chair, corporate governance, strategic alternative transaction, Nasdaq